Navigation Links
Drug in new class of targeted therapies shows early promise against blood-related cancers
Date:5/19/2010

and colleagues tested the new medication on 37 patients, 19 with CLL and 18 with myeloma. Patients recruited to the study had advanced disease that was in relapse, and all had been through previous treatments with other medications (median number of prior treatments: four). All patients were given SNS-032, and all were aware of what they were taking.

To test both the drug's safety and the best potential dose, SNS-032 was given intravenously as a "loading" dose an initially higher dose that is then reduced to a maintenance level over five minutes. This was followed by a six-hour infusion given to all patients on a weekly basis for three consecutive weeks.

Although the primary purpose of the study was to test the maximum safe dose that could be given to patients, Dr. Siegel and colleagues also looked at whether the medication had an effect on disease processes. One patient with CLL had more than a 50 percent reduction in measurable disease, but no improvement in disease markers in the blood. Another CLL patient had stable disease for four courses of treatment. For multiple myeloma, two patients had stable disease with treatment and one had normalization of spleen size, which is an indication of a reduction in blood cancer activity.

Looking at blood test results for the patients, the researchers found anti-cancer activity. The drug appeared to inhibit cyclindependent kinases 7 and 9, two of the three enzymatic proteins targeted in this study. They also caused apoptosis, or cell death, in cancer cells.

"Our study found that this drug is well tolerated and had some clinical effect, but it is important to note that this was a small, very early stage study," says Dr. Siegel. "Based on these findings, there is justification for additional research, which will show whether this drug has a place in the arsenal of treatments for hematologic malignancies."

Preclinical studies of SNS-032 demonstrated that the drug inhibited th
'/>"/>

Contact: Amy Leahing
amy.leahing@widmeyer.com
646-213-7245
John Theurer Cancer Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Retirement Community in Arizona Hosts Classic Car Show with Live Music
2. ‘Best in Class' Nursing Homes Recognized for Exemplary Customer, Workforce Satisfaction
3. Martin & Jones Announces Class Action Lawsuit Against Major Employer, Claims Thousands of Visiting Nurses Illegally Denied Overtime Pay
4. A medicine classic goes online and far afield
5. MetaGeek Announces Chanalyzer Pro Spectrum Analysis Software for Wi- Spy, Adds Device Classification, Device Finder and Automated Reports
6. Classic Maya history is embedded in commoners homes
7. New class of drug kills lymphoma cells
8. Exposure to 3 classes of common chemicals may affect female development
9. HealthLinkRx Announces Classes in Spanish for Occupational and Physical Therapists
10. Dr. Khanna to Attend the 13th annual Women in Film Malibu Golf Classic
11. Bad Habits Explain Class Differences in Health: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... (PRWEB) July 11, 2014 Recently, iFitDress.com, ... special occasion outfits, has released its new collection of ... that, the company has announced that all these beautiful ... off. The deadline of the special offer is July ... its major officials pay close attention to customer satisfaction. ...
(Date:7/11/2014)... Organic Crop Farming in ... the limelight over the past decade. According to IBISWorld ... to be an alternative food eaten only by minority ... organic food.” Organic crop farmers have reaped the benefits ... and herbs over the past five years. Industry revenue ...
(Date:7/11/2014)... era of personalized medicine may be just around the ... researcher Min Yu and scientists at Massachusetts General Hospital ... study in Science , Yu and her colleagues ... the blood streams of six patients. Some of these ... travel to and establish secondary tumors in vital organs ...
(Date:7/11/2014)... Alliance Labs announced that they will be featured ... Jr, airing later this year 2014, via Discovery Channel. ... Innovations will explore DocuSol® Kids, a mini-enema containing a ... base designed to give adolescents general constipation relief. Viewers ... hyperosmotic laxative by drawing water into the bowel from ...
(Date:7/11/2014)... Cruciate Ligament (ACL) reconstructions occur more than 200,000 times ... create a new ligament may determine how long you ... today at the Annual Meeting of the American Orthopaedic ... study results highlight that in a young athletic population, ... than using autografts (tissue harvested from the patient)," said ...
Breaking Medicine News(10 mins):Health News:Worldwide Chic Ladies Can Buy Cheap Evening Dresses at iFitDress.com 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 4Health News:Alliance Labs & DocuSol® to be Featured in Upcoming Episode of Innovations 2Health News:ACL reconstructions may last longer with autografts 2
... efforts to unlock therapeutic potential , , MONDAY, Feb. 9 ... Obama,s anticipated lifting of the eight-year ban on embryonic ... W. Bush. , The anticipation moved one step closer ... House Democrats at a closed-door Virginia retreat a "guarantee" ...
... Inc. (Nasdaq: BNVI ) announced today the ... company,s Scientific Advisory Board. Dr. Gustafsson has extensive experience ... biotech companies. "We are very excited to have Dr. ... advancing our discovery platforms," said Isaac Cohen, O.M.D., Bionovo,s ...
... Fla., Feb. 9 MEDai, Inc., a leading provider ... it is offering a free case study on its ... analytic solution Risk Navigator Clinical(R) and its,application to keep ... The case study explores how one of MEDai,s ...
... -- Mindray Medical,International Limited (NYSE: MR ... devices worldwide, today announced that it will report ... year ended December 31,2008, after the U.S. market ... an earnings conference call at 8:00 AM on ...
... during 2008 holiday shopping seasonFORT WORTH, Texas, Feb. 9 ... customers, raised nearly $1.5 million for the fifth-annual ... fundraising initiative for St. Jude Children,s Research Hospital that ... , Customers who shopped at RadioShack stores had the ...
... supplement is the real deal. Extreme Endurance is a 100% ... certified drug-free by the world,s largest sports drug laboratory. In a ... lactic acid was reduced by 15%. This was a 30 day ... ...
Cached Medicine News:Health News:Scientists Heartened at Prospect of End to Stem Cell Ban 2Health News:Scientists Heartened at Prospect of End to Stem Cell Ban 3Health News:Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovo's Scientific Advisory Board 2Health News:Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovo's Scientific Advisory Board 3Health News:Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovo's Scientific Advisory Board 4Health News:Health Plans Use MEDai to Forecast, Rank Risk and Drive Interventions 2Health News:Mindray to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 4, 2009 2Health News:RadioShack Helps Raise $1.5 Million for St. Jude Children's Research Hospital(R) Fifth-Annual Thanks and Giving(R) Campaign 2Health News:RadioShack Helps Raise $1.5 Million for St. Jude Children's Research Hospital(R) Fifth-Annual Thanks and Giving(R) Campaign 3Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 2Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 3Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 4Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 5
(Date:7/11/2014)... 11, 2014 According to a ... Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) ... Forecast, 2013-2019" the global endoscopy devices market was valued ... to grow at a CAGR of 6.8% from 2013 ... 36.9 billion in 2019. Browse the full ...
(Date:7/10/2014)... , July 11, 2014  Major advances in ... cancer are being highlighted in a three-day Oncology ... from 10-12 July, 2014.  Renowned national and international cancer ... best practices and exchange knowledge on modern technologies ... and efficient. The Summit will ...
(Date:7/10/2014)... DIEGO , July 10, 2014  RESMED INC. (NYSE: ... its fourth quarter and fiscal year ended June 30, 2014 ... Stock Exchange market close. A press release with ResMed,s results ... the company will host a webcast to discuss operating results ... to begin at 1:30 p.m. US Pacific Time and the ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Alere Inc. (NYSE: ALR ) announced today ... notes due 2018 through a private placement, subject to market ... from the offering for working capital and other general corporate ... commence immediately, will be to qualified institutional buyers in reliance ...
... (Nasdaq: PCYC ) today reported financial results for its ... During the fiscal year ended June 30, 2010, total ... in the fiscal year ended June 30, 2009.  The GAAP net ... $15.0 million, or $0.31 per share. This compares to a GAAP ...
Cached Medicine Technology:Alere Inc. Announces Offering of $350 Million of Senior Subordinated Notes 2Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 2Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 3Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 4Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 5Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 6Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 7Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 8Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 9Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 10Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 11Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 12Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 13Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 14
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Girard curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 99 mm....
Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm....
Curved tying forceps made of titanium has curved shafts with 6 mm V-grove tying platforms, width of shafts 0,5 mm, TCI platforms, flat handle, width 10 mm, overall length 103 mm....
Medicine Products: